BlossomHill Therapeutics reports Q2 net loss and upsized IPO
BlossomHill Therapeutics reported a Q2 2026 net loss of $23.8M, ended June with $95.4M cash, and raised $168.3M gross in an upsized IPO. The company expects cash to fund operations into Q2 2028.
8M as research and development and general and administrative costs increased. 4M in cash. 3M gross in an upsized IPO and expects that cash to fund operations into Q2 2028.